Clinical Trial Update: ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Deficiency [Phase 3]

View source ↗

Summary

This clinical trial update notes that INZ-701 is in Phase 3 trials to evaluate efficacy and safety in infants with ENPP1 deficiency, Autosomal recessive hypopho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Recessive Hypophosphatemic Rickets
• Enpp1 Deficiency
• Generalized Arterial Calcification of Infancy

Drugs mentioned

• INZ-701

Snippet

Sponsor: Inozyme Pharma | Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 3 | Status: RECRUITING